The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)
NCT ID: NCT00449813
Last Updated: 2012-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
40 participants
INTERVENTIONAL
2007-03-31
2008-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)
NCT00336219
Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Non-erosive Reflux or Gastroesophageal Reflux Disease (BY1023/DE-004)
NCT00326027
Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)
NCT00246909
Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Symptoms of Non-Erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (eGERD)
NCT00561730
Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)
NCT00163306
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1.
40 mg Pantoprazole
Pantoprazole
40 mg Pantoprazole
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pantoprazole
40 mg Pantoprazole
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Outpatients of at least 18 years of age
* History of GERD-related symptoms of at least 6 months prior to baseline visit
* Endoscopically-confirmed GERD or non-erosive GERD
Exclusion Criteria
* Acute peptic ulcer and/or ulcer complications
* Pyloric stenosis
* Severe or unstable cardiovascular, pulmonary, and/or endocrine disease
* Pregnancy, breast feeding, intention to become pregnant during the course of the study or lack of reliable contraception in women of child-bearing potential
* Intake of any medication for the purpose of eradication of Helicobacter pylori (H. pylori) within the last 28 days prior to study start
* Intake of systemic glucocorticoids or non-steroidal anti-inflammatory drugs including cyclooxygenase-2 (COX-2) inhibitors for more than 3 consecutive days within the last 28 days prior to study start; with the exception of acetylsalicylic acid not more than 150 mg per day
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nycomed
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
M. Oudkerk Pool, Prof.
Role: PRINCIPAL_INVESTIGATOR
Isala Klieniken, Zwolle, The Netherlands
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Altana Pharma/Nycomed
BT Oss, , Netherlands
Altana Pharma/Nycomed
Den Helder, , Netherlands
Altana Pharma/Nycomed
EH Geldrop, , Netherlands
Altana Pharma/Nycomed
Basel, , Switzerland
Altana Pharma/Nycomed
Basel, , Switzerland
Altana Pharma/Nycomed
Biel/Bienne, , Switzerland
Altana Pharma/Nycomed
Bülach, , Switzerland
Altana Pharma/Nycomed
Locarno, TI., , Switzerland
Altana Pharma/Nycomed
Lucerne, , Switzerland
Altana Pharma/Nycomed
Lucerne, , Switzerland
Altana Pharma/Nycomed
Reinach, , Switzerland
Altana Pharma/Nycomed
Sion, , Switzerland
Altana Pharma/Nycomed
Thun, , Switzerland
Altana Pharma/Nycomed
Winterthur, , Switzerland
Altana Pharma/Nycomed
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BY1023/NL511
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.